PRA Nominated For 'Best CRO' Award In Global Contest

PRA, a leading Clinical Research Organization, announces that it is a finalist in the category of Best CRO Award for the 3rd annual BioPharma Asia Industry Awards 2013. The winner will be determined by an online voting contest. Voting is currently open and closes March 8, with the winners announced March 19 at an awards dinner in Singapore.

“It’s an honor to be nominated for the ‘Best CRO Award’,” said Kent Thoelke, PRA Executive Vice President, Scientific and Medical Affairs. “Our recent joint venture with WuXi PharmaTech in China is just another of the many steps we have taken to further enhance our ability to provide excellent service in Asia’s biopharmaceutical market.”

Organized by Terrapinn, a business media company, the awards honor and generate public recognition of the efforts, accomplishments and positive contributions of organizations and individuals in Asia’s biopharmaceutical industry. The awards also identify and reward organizations and individuals who have demonstrated an unparalleled ability to succeed, continually set standards of excellence and who will be the future stars of the biopharmaceutical industry.

There are nine award categories: Best LSP Award; Best Contract Research Organization Award; Best Contract Manufacturing Organization Award; Most Innovative Asian Biotech Award; Asian Executive of the Year; Woman Executive of the Year; Best Manufacturing Solution Provider Award; Best Drug Pipeline Award; and Pharma Company of the Year.

About PRA
PRA is transforming clinical trials through our people, innovation and transparency. PRA provides personalized service customized to the unique requirements of each study. We support our global reach and innovative approach through flexible and reliable service, delivered by skilled employees dedicated to ensuring that sponsors achieve their long-term goals.

We serve our clients across all phases of pharmaceutical and biotech drug development by combining therapeutic and operational expertise with local knowledge. Offering services in 80+ countries and serving sponsors for 30+ years, we have amassed a level of expertise that has enabled us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs. But at PRA, we are looking to the future, not the past. Our increasingly forward-thinking approach to transforming the clinical trial landscape will continue to make a difference to healthcare patients around the world. For more information, visit praintl.com